Last reviewed · How we verify
PT-112
At a glance
| Generic name | PT-112 |
|---|---|
| Also known as | Gemcitabine, PT-112 |
| Sponsor | Promontory Therapeutics Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- PT-112 in Subjects With Thymoma and Thymic Carcinoma (PHASE2)
- A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts (PHASE2)
- A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab (PHASE1, PHASE2)
- PT-112 (Phosplatin's Platinum) Combine With Gemcitabine Injection for Advanced Solid Tumors (PHASE1, PHASE2)
- A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma (PHASE1)
- An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study (PHASE1, PHASE2)
- An Open-label Phase I/II Clinical Trial of PT-112 Injection for Advanced Solid Tumors and Advanced Hepatocellular Carcinoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PT-112 CI brief — competitive landscape report
- PT-112 updates RSS · CI watch RSS
- Promontory Therapeutics Inc. portfolio CI